Everything We’re Saying, and Everything Being Said About Us
Explore the stories behind our science and the people it serves.
Subscribe to Our Monthly Newsletter
Each month, we will send key data updates, stories from the field, and new research on inclusive oncology AI.
Highlight of the Month
PAICON and NVIDIA Spotlight Sovereign AI at AI Week
PAICON and NVIDIA jointly highlighted the future of Sovereign AI at AI Week.
From Germany to the UK: PAICON at Cambridge Tech Week
We joined the Cambridge Tech Week 2025, where innovation meets community and ideas move seamlessly between research, industry, and entrepreneurship....
PAICON at the MSI Symposium Heidelberg 2025
Dr. Witali Aswolinskiy, AI Lead at PAICON, delivered a talk at the European Symposium on Tumors with Microsatellite Instability (MSI)...
PAICON at WHX Tech 2025: Driving Equity in Cancer Diagnostics
We exhibited at WHX Tech 2025, presenting our vision of transforming cancer care with genetically and technically diverse data combined...
Equity in Clinical Trials: Closing the Participation Gap
Clinical trials are the foundation of progress in cancer care. Yet participation in clinical trials remains unequal.
Remaining84 in Real Life: The Danger of Ignoring Genetic Diversity in Precision Medicine
At Indiana University's Precision Genomics Clinic, a breast cancer patient's standard chemotherapy treatment took a devastating turn. What should have...
Patient - Clinician Communication in the Age of AI
AI is transforming healthcare, bringing powerful tools for diagnostics, treatment planning, and patient management. Yet as technology becomes embedded in...
Data Diversity and Social Barriers: Addressing Racial Disparities in Breast Cancer Outcomes
Breast cancer is the most common cancer among women worldwide, but outcomes are not equal across population due to racial...
PAICON Featured in FOUND - Startup Magazine Heidelberg
PAICON has been featured in FOUND – Startup Magazin Heidelberg, where our mission, innovations, and flagship AI solutions like SatSight...
The Remaining84 in Real Life: A Common Cancer Drug Took Her Life Instead of Saving
A 60-year-old woman’s tragic reaction to a common cancer drug exposes the Remaining84 problem: the 84% of the world’s population...
Subscribe to Our Monthly Newsletter
Each month, we will send key data updates, stories from the field, and
new research on
inclusive oncology AI.